Wael El-Rifai Archives
Early drivers of gastric cancer
Aug. 8, 2017—Using bioinformatics approaches, Vanderbilt investigators have identified gene expression networks that are deregulated in mouse and human stomach cancers.
Esophageal cancer complexities
Mar. 16, 2017—New findings that reveal complex interactions in esophageal adenocarcinoma could lead to diagnostic, prognostic or therapeutic biomarkers.
Improving therapies for GI tumors
Feb. 20, 2017—A signaling protein overexpressed in upper gastrointestinal cancers is an attractive therapeutic target.
Nine Vanderbilt faculty members elected AAAS fellows
Nov. 25, 2016—Nine Vanderbilt University faculty members have been elected fellows of the American Association for the Advancement of Science this year.
A DARPP role in gastric cancer
Nov. 3, 2016—Vanderbilt researchers have discovered a link between Helicobacter pylori infection, inflammation and gastric cancer that could suggest new anti-cancer therapies.
Stomach cancer cues
Aug. 6, 2015—Vanderbilt scientists have discovered a new molecular mechanism that promotes stomach cancer development, findings that could provide new opportunities for treatment.
Therapeutic target for gastric cancer
Dec. 12, 2013—A protein kinase linked to inflammation and tumor development may be a good target for gastric cancer therapies.
Dual-action enzyme protects esophagus
May. 9, 2013—An antioxidant enzyme also functions as a tumor suppressor to limit cancer development in the esophagus.
Enzyme counters stomach acid attack
Sep. 11, 2012—Dysfunction or loss of an “antioxidant” enzyme may lead to higher risk for esophageal cancer in patients with gastric reflux disease.
Heart protein may be target for colon cancer therapies
Oct. 7, 2011—A protein critical in heart development may also play a part in colon cancer progression.